BACKGROUND: The prognosis of colorectal cancer patients is to a considerable extent determined by the metastatic potency of the primary tumor. However, despite the fact that liver metastases are the leading cause of death for cancer patients, the molecular basis still remains poorly understood and independent prognostic markers have not been established. MATERIALS AND METHODS: Comparative genomic hybridization (CGH) was used to screen colorectal carcinomas without distant metastases (n=18) and carcinomas synchronously metastatic to the liver (n=18). We aimed to detect distinct chromosomal aberrations indicating a metastatic phenotype. RESULTS AND DISCUSSION: Metastatic tumors exhibited a significantly (P=0.03) higher ANCA value (13.8) if compared with non-metastatic cancers (10.0). Furthermore, we observed that losses of chromosomal regions 1p32-ter and 9q33-ter were present at much higher frequencies in metastatic than in non-metastatic cancers, respectively (P=0.02 and 0.04). CONCLUSION: These data indicate that metastatic tumors may be separated from non-metastatic colorectal cancers based on their genomic profile.
BACKGROUND: The prognosis of colorectal cancerpatients is to a considerable extent determined by the metastatic potency of the primary tumor. However, despite the fact that liver metastases are the leading cause of death for cancerpatients, the molecular basis still remains poorly understood and independent prognostic markers have not been established. MATERIALS AND METHODS: Comparative genomic hybridization (CGH) was used to screen colorectal carcinomas without distant metastases (n=18) and carcinomas synchronously metastatic to the liver (n=18). We aimed to detect distinct chromosomal aberrations indicating a metastatic phenotype. RESULTS AND DISCUSSION: Metastatic tumors exhibited a significantly (P=0.03) higher ANCA value (13.8) if compared with non-metastatic cancers (10.0). Furthermore, we observed that losses of chromosomal regions 1p32-ter and 9q33-ter were present at much higher frequencies in metastatic than in non-metastatic cancers, respectively (P=0.02 and 0.04). CONCLUSION: These data indicate that metastatic tumors may be separated from non-metastatic colorectal cancers based on their genomic profile.
Authors: José María Sayagués; Celia Fontanillo; María del Mar Abad; María González-González; María Eugenia Sarasquete; Maria del Carmen Chillon; Eva Garcia; Oscar Bengoechea; Emilio Fonseca; Marcos Gonzalez-Diaz; Javier De las Rivas; Luís Muñoz-Bellvis; Alberto Orfao Journal: PLoS One Date: 2010-10-29 Impact factor: 3.240
Authors: Hisham Eldai; Sathish Periyasamy; Saeed Al Qarni; Maha Al Rodayyan; Sabeena Muhammed Mustafa; Ahmad Deeb; Ebthehal Al Sheikh; Mohammed Afzal; Mohammed Afzal Khan; Mishal Johani; Zeyad Yousef; Mohammad Azhar Aziz Journal: PLoS One Date: 2013-10-30 Impact factor: 3.240
Authors: María González-González; Luís Muñoz-Bellvis; Carlos Mackintosh; Celia Fontanillo; M Laura Gutiérrez; M Mar Abad; Oscar Bengoechea; Cristina Teodosio; Emilio Fonseca; Manuel Fuentes; Javier De Las Rivas; Alberto Orfao; José María Sayagués Journal: PLoS One Date: 2012-08-17 Impact factor: 3.240